Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval
By Ben Glickman
Catalyst Pharmaceuticals said that it would commercially launch Agamree, a treatment for Duchenne Muscular Dystrophy, after the treatment was approved by the U.S. Food and Drug Administration.
Catalyst holds the exclusive North American license to commercialize Agamree, which was developed by Santhera Pharmaceuticals. Catalyst secured the rights in July.
The Coral Gables, Fla.-based pharmaceutical company said Thursday that Agamree oral suspension of 40 mg/ml had been approved by the FDA to treat Duchenne in patients two years and older. Catalyst plans to launch commercially in the first quarter of 2024.
The treatment was Orphan Drug and Rare Pediatric Disease status for Duchenne in the U.S., meaning Catalyst will have exclusivity for seven years.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 26, 2023 15:49 ET (19:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase